230 related articles for article (PubMed ID: 35156867)
1. Clinical and economic burden of HPV-related cancers in the US veteran population.
Saxena K; Dawson RS; Cyhaniuk A; Bello T; Janjan N
J Med Econ; 2022; 25(1):299-308. PubMed ID: 35156867
[TBL] [Abstract][Full Text] [Related]
2. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
[TBL] [Abstract][Full Text] [Related]
3. Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States.
Prabhu V; Kathe N; Saxena K; Walia A; Markan R; Myers E; Einstein M
Curr Med Res Opin; 2021 Sep; 37(9):1599-1607. PubMed ID: 34018457
[TBL] [Abstract][Full Text] [Related]
4. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
Chaturvedi AK
J Adolesc Health; 2010 Apr; 46(4 Suppl):S20-6. PubMed ID: 20307840
[TBL] [Abstract][Full Text] [Related]
5. Risk of human papillomavirus-associated cancers among persons with AIDS.
Chaturvedi AK; Madeleine MM; Biggar RJ; Engels EA
J Natl Cancer Inst; 2009 Aug; 101(16):1120-30. PubMed ID: 19648510
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
7. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
[TBL] [Abstract][Full Text] [Related]
8. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
[TBL] [Abstract][Full Text] [Related]
9. Prevention and Screening of HPV Malignancies.
Dahlstrom KR; Day AT; Sturgis EM
Semin Radiat Oncol; 2021 Oct; 31(4):297-308. PubMed ID: 34455985
[TBL] [Abstract][Full Text] [Related]
10. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
[TBL] [Abstract][Full Text] [Related]
11. Five-year relative survival for human papillomavirus-associated cancer sites.
Razzaghi H; Saraiya M; Thompson TD; Henley SJ; Viens L; Wilson R
Cancer; 2018 Jan; 124(1):203-211. PubMed ID: 29105738
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive control of human papillomavirus infections and related diseases.
Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
[TBL] [Abstract][Full Text] [Related]
13. Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.
Choi I; Lee D; Son KB; Bae S
BMC Public Health; 2020 Jun; 20(1):1035. PubMed ID: 32600300
[TBL] [Abstract][Full Text] [Related]
14. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
15. Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review.
Lekoane KMB; Kuupiel D; Mashamba-Thompson TP; Ginindza TG
BMC Cancer; 2019 Jun; 19(1):563. PubMed ID: 31185951
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
17. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
Kiellberg Larsen H; Kofoed K; Sand C
Ugeskr Laeger; 2013 Feb; 175(6):349-53. PubMed ID: 23402241
[TBL] [Abstract][Full Text] [Related]
18. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods.
Watson M; Saraiya M; Ahmed F; Cardinez CJ; Reichman ME; Weir HK; Richards TB
Cancer; 2008 Nov; 113(10 Suppl):2841-54. PubMed ID: 18980203
[TBL] [Abstract][Full Text] [Related]
19. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
Bogaards JA; Wallinga J; Brakenhoff RH; Meijer CJ; Berkhof J
BMJ; 2015 May; 350():h2016. PubMed ID: 25985328
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
